Results 101 to 110 of about 60,513 (321)
Response: CEBPA promoter hypermethylation in a subset of myeloid/T-lymphoid leukemias with a distinct gene expression profile [PDF]
, 2009 Background: Systemic mastocytosis is a rare myeloproliferative disease characterized by the uncontrolled proliferation of aberrant mast cells. It has varying clinical manifestations.
Bas Wouters +3 more
core +7 more sources
Blood Cancer Journal, 2021 Myelofibrosis is a myeloproliferative neoplasm associated with constitutional symptoms, increasing splenomegaly, and worsening cytopenias. Janus kinase (JAK) inhibitors have been used for the treatment of myelofibrosis for several years, but there is a ...
Léa Sureau +6 more
semanticscholar +1 more source
Methylation of TET2, CBL and CEBPA in Ph-negative myeloproliferative neoplasms [PDF]
, 2010 A loss-of-function mutation of TET2, CBL and CEBPA has been implicated in the pathogenesis or leukaemic transformation of myeloproliferative neoplasm.
Chim, CS, Fung, TK, Wan, TS, Wong, KF
core +1 more source
British Journal of Haematology, EarlyView.Treatment with pegylated interferon α resulted in a molecular response in 91% of patients with an average decrease in JAK2V61F VAF of 48.5% from baseline. In patients that discontinued treatment, the JAK2V617F VAF at the time of treatment discontinuation was the best indicator of durable remission over the 6‐month follow‐up period.
Ryan Brown +13 more
wiley +1 more source
Blood, 2019 Allogeneic hematopoietic stem cell transplantation is curative in myelofibrosis, and current prognostic scoring systems aim to select patients for transplantation.
N. Gagelmann +13 more
semanticscholar +1 more source
Efficacy of Momelotinib in Myelofibrosis Patients: Results From a Multicenter Study
European Journal of Haematology, EarlyView.ABSTRACT Momelotinib, a novel JAK1/2 inhibitor with inhibitory activities on activin A receptor type I, has shown breakthrough clinical efficacy in patients with myelofibrosis (MF) and anemia, a disease‐related manifestation of challenging management. In this retrospective real‐life multicenter Italian study, we investigated the safety and efficacy of ...
Maria Carmen Martorelli +34 more
wiley +1 more source
Haematologica, 2019 In this study we interrogated the DNA methylome of myelofibrosis patients using high-density DNA methylation arrays. We detected 35,215 differentially methylated CpG, corresponding to 10,253 genes, between myelofibrosis patients and healthy controls ...
Nicolás Martínez-Calle +15 more
doaj +1 more source
Archives of Disease in Childhood, 1980 Two siblings developed a fulminant fatal myeloproliferative disease at 7 and 8 weeks of age. The illness presented with pallor, haemorrhagic symptoms, and hepatosplenomegaly, and the blood picture was that of pancytopenia and leucoerythroblastosis. Bone marrow histology showed reduced haemopoiesis with generalised fibrosis.
C A, Sieff, P, Malleson
openaire +2 more sources
Translocation (2;3)(p21;q26) as the sole anomaly in a case of primary myelofibrosis. [PDF]
, 1999 peer reviewedTranslocation t(2p;3q) is a rare but recurrent finding in myeloid disorders. We present the first case of primary myelofibrosis with t(2;3)(p21;q26) as the sole chromosomal anomaly.
Albert Thiry +22 more
core +1 more source
European Journal of Haematology, EarlyView.ABSTRACT Previous studies investigating the role of TP53 mutations in chronic phase MPN have yielded inconsistent results. As such, the clinical relevance of these mutations remains to be elucidated. We report a case of a 67‐year‐old woman with a leukemic transformation of a post‐polycythaemia vera myelofibrosis (post‐PV MF) that culminated in the rare
Isidor Minović +8 more
wiley +1 more source